01 Industry overview
The alzheimers biologics industry at a glance
The Alzheimer’s biologics industry is expanding clinically: 54 biological therapies were in development across 192 Alzheimer’s trials as of January 1, 2026, while commercial adoption remains concentrated in anti-amyloid antibodies.
- 54[1]
- Biologic therapies in pipeline, 2026
- 192[1]
- Active Alzheimer’s trials, 2026
- $177.7M[4]
- Biogen Leqembi revenue share, 2025
- $28,270[5]
- Annual Leqembi IV list price, 2026
- Market share & regions
- Commercial biologics activity is concentrated in the United States and other markets where anti-amyloid antibodies are approved and reimbursed. In the 2026 development pipeline, 12% of Phase 3 trials were conducted only in North America, 24% only outside North America, and 63% in both regions.[1]
- Segmentation
- The 2026 pipeline contained 158 drugs across 192 trials. Biological therapies represented 54 of 116 disease-targeted therapies, or 47%; among disease-targeted therapies, 25 agents targeted amyloid-beta-related processes and 15 targeted tau-related processes.[1]
- Key players & concentration
- The commercial market is concentrated around Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla, the two leading approved disease-modifying anti-amyloid biologics. In clinical development, biopharmaceutical companies sponsored 72% of Phase 3 Alzheimer’s trials and 61% of Phase 3 drugs in the 2026 pipeline.[1][6]
- Pricing
- Leqembi’s July 2026 U.S. list-price example was $28,270.32 per year for a 165-pound patient receiving twice-monthly IV treatment, excluding diagnostic, monitoring, and administration costs. Its weekly subcutaneous maintenance presentation was listed at $20,020 annually after the initial 18-month dosing period.[5]
- Trends, drivers & challenges
- Pipeline activity is broadening beyond amyloid: the 2026 pipeline included 28 agents targeting inflammation or immune processes, 25 targeting amyloid-beta-related pathology, and 15 targeting tau. Major constraints include safety monitoring, high development failure rates, and limited real-world uptake; the review reported no new Alzheimer’s drug approvals since 2023.[1][7]
- Consumer behavior & competition
- Patient access is concentrated in early Alzheimer’s disease because Leqembi is indicated for mild cognitive impairment or mild dementia stages and requires confirmed amyloid pathology plus MRI monitoring. Competition is primarily between Leqembi, administered on a weight-based schedule, and Kisunla, an anti-amyloid antibody approved by the FDA on July 2, 2024.[8][6]
- Regulation
- U.S. Medicare coverage for FDA-approved monoclonal antibodies directed against amyloid is provided under Coverage with Evidence Development for patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia. Leqembi labeling requires confirmation of amyloid pathology, a recent baseline MRI, and additional MRIs during treatment to monitor for amyloid-related imaging abnormalities.[9][8]
- Latest news
- On July 13, 2026, the FDA approved the first at-home starting dose for an Alzheimer’s disease treatment, expanding Leqembi’s administration options beyond infusion-center initiation. The 2026 pipeline review also identified 59 new Alzheimer’s trials compared with the January 1, 2025 index date.[6][1]
02 Ranking
Top 10 Companies in the Alzheimers Biologics Industry
The leading companies in the alzheimers biologics industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 18, 2026 · Next review December 18, 2026
Eli Lilly and Company stands out for early Alzheimer’s anti-amyloid antibody work because it markets Kisunla for early Alzheimer’s disease, while Eisai focuses on Leqembi since it leads global Leqembi development and regulatory submissions with Biogen.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in anti-amyloid antibodies
Eli Lilly and Company
US
Ranked #1 · 9.9 · Anti-amyloid antibodies
Why we picked it: Kisunla targets early Alzheimer’s via an approved anti-amyloid antibody, while Lilly also reports an operating margin of 40.4%.
Leader in alzheimer’s biologic development partnerships
Eisai
JP
Ranked #2 · 9.1 · Alzheimer’s biologic development partnerships
Why we picked it: Eisai leads Leqembi development and regulatory submissions with Biogen and allocates R&D equal to 23% of revenue.
Leader in alzheimer’s biologic pipeline
Roche
CH
Ranked #3 · 9.0 · Alzheimer’s biologic pipeline
Why we picked it: Roche’s Alzheimer’s portfolio includes investigational trontinemab and other biologic candidates, with R&D at 19.8% of revenue.
Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Eli Lilly and Company Anti-amyloid antibodies · US | 9.9 | 9.9 | 9.9 | 9.9 | 9.9 | |
Company snapshot · Eli Lilly and Company · Data as of November 18, 2026 Lilly markets Kisunla, an approved anti-amyloid antibody for early Alzheimer’s disease.[10]
| |||||||
| 2 | Eisai Alzheimer’s biologic development partnerships · JP | 9.1 | 9.2 | 9.0 | 9.1 | 9.3 | |
Company snapshot · Eisai · Data as of November 18, 2026 Eisai leads global Leqembi development and regulatory submissions with Biogen.[11]
| |||||||
| 3 | Roche Alzheimer’s biologic pipeline · CH | 9.0 | 8.9 | 8.4 | 9.0 | 9.9 | |
Company snapshot · Roche · Data as of November 18, 2026 Roche’s Alzheimer’s portfolio includes investigational trontinemab and other biologic candidates.[12]
| |||||||
| 4 | Johnson & Johnson Tau immunotherapies · US | 8.6 | 8.4 | 8.3 | 8.7 | 9.3 | |
Company snapshot · Johnson & Johnson · Data as of November 18, 2026 Janssen, a Johnson & Johnson company, partners with AC Immune on anti-tau immunotherapy.[13]
| |||||||
| 5 | Biogen Alzheimer’s biologic manufacturing · US | 8.5 | 9.3 | 8.0 | 7.6 | 8.7 | |
Company snapshot · Biogen · Data as of November 18, 2026 Biogen shares Leqembi economics and manufactures its drug substance for Eisai.[14]
| |||||||
| 6 | Bristol Myers Squibb Tau antibody programs for Alzheimer’s · US | 8.4 | 8.4 | 7.8 | 8.1 | 9.3 | |
Company snapshot · Bristol Myers Squibb · Data as of November 18, 2026 Bristol Myers Squibb is developing moponetug, an investigational tau antibody for Alzheimer’s disease.[15]
| |||||||
| 7 | Denali Therapeutics Brain-shuttle antibodies for Alzheimer’s · US | 8.2 | 7.6 | 8.2 | 8.7 | 8.9 | |
Company snapshot · Denali Therapeutics · Data as of November 18, 2026 Denali’s DNL921 is an antibody transport vehicle designed to target amyloid plaques in Alzheimer’s.[16]
| |||||||
| 8 | Alzinova Oligomer-targeting Alzheimer’s vaccines and antibodies · SE | 7.6 | 7.0 | 7.6 | 8.2 | 8.0 | |
Company snapshot · Alzinova · Data as of November 18, 2026 Alzinova is developing ALZ-101, an active immunotherapy vaccine for Alzheimer’s disease.[17]
| |||||||
| 9 | AC Immune Alzheimer’s vaccines and anti-tau immunotherapies · CH | 7.5 | 7.6 | 7.0 | 7.5 | 8.0 | |
Company snapshot · AC Immune · Data as of November 18, 2026 AC Immune develops ACI-24 and ACI-35 active immunotherapies for Alzheimer’s disease.[18]
| |||||||
| 10 | Vaxxinity Active immunotherapy vaccines for Alzheimer’s · US | 7.1 | 7.0 | 7.6 | 7.0 | 7.0 | |
Company snapshot · Vaxxinity · Data as of November 18, 2026 Vaxxinity’s UB-311 is an investigational vaccine targeting toxic aggregated amyloid beta in Alzheimer’s.[19]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 18, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 19). Top 10 companies in the alzheimers biologics industry. In Alzheimers Biologics Industry Statistics. Gitnux. https://gitnux.org/alzheimers-biologics-industry-statistics/#top-companies
Global Alzheimer's disease drug development pipeline composition by therapy type
Small-molecule disease-targeting therapies holds the largest share at 39%.
03 Trends & forecasts
Top 10 Alzheimers Biologics Industry Trends & Forecasts 2027
What is changing in the alzheimers biologics industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Biologic pipeline expands beyond amyloid
High confidenceThe January 1, 2026 pipeline contained 54 biological therapies across 192 Alzheimer’s trials. Biological therapies represented 47% of the 116 disease-targeted therapies, indicating that biologics remain central to development while expanding beyond commercial anti-amyloid products.[1]
Forecast 2027: In 2027, biologics should remain the largest strategic segment of Alzheimer’s disease-modifying development, with additional programs entering Phase 1 and Phase 2. Commercial activity will still be concentrated in anti-amyloid antibodies, but the pipeline mix should become more diversified.
02Clinical development volume continues rising
High confidenceThe 2026 review identified 192 active Alzheimer’s trials assessing 158 drugs, up from 182 trials assessing 138 drugs in the 2025 pipeline. It also recorded 59 trials newly added since January 1, 2025.[1]
Forecast 2027: The number of active trials is likely to increase again in 2027, although growth should be slower than the expansion in drug candidates because several early programs will terminate or consolidate after clinical readouts.
03Late-stage biologic competition intensifies
High confidenceThe 2026 pipeline included 54 Phase 3 trials studying 36 drugs; 11 of the 21 Phase 3 disease-targeted therapies were biologics. Commercial competition is currently led by Leqembi and Kisunla, both amyloid-beta-directed antibodies.[1][20]
Forecast 2027: In 2027, competition should focus less on the arrival of an entirely new biologic class and more on differentiation through dosing frequency, safety, treatment duration, brain penetration and evidence of functional benefit.
04Inflammation targets gain momentum
High confidenceInflammation and immune processes were the largest disease-pathology category in the 2026 pipeline, with 28 agents, compared with 25 agents targeting amyloid-beta-related processes and 15 targeting tau-related processes.[1]
Forecast 2027: In 2027, immune-modulating biologics should attract more partnering and translational research interest, particularly where developers can link immune mechanisms to validated biomarkers and reduce the safety risks associated with broad immune activation.
05Tau biologics move toward validation
Medium confidenceThe 2026 pipeline included 15 tau-targeting agents, including tau monoclonal antibodies, vaccines and RNA-based approaches. The review also listed Phase 1 tau biologics with primary completion dates in 2027.[1]
Forecast 2027: During 2027, tau programs should generate more early clinical and biomarker data, but tau biologics are unlikely to displace anti-amyloid antibodies commercially unless they demonstrate a clear benefit after amyloid removal or in patients with limited amyloid burden.
06Combination biologics enter clinical testing
Medium confidenceThe 2026 pipeline included Phase 2 combination studies involving a tau vaccine and an anti-amyloid monoclonal antibody, as well as other multi-target approaches. Nine pipeline drugs were classified as multi-target agents.[1]
Forecast 2027: In 2027, combination strategies should expand mainly in early-stage trials, testing whether sequential or simultaneous targeting of amyloid, tau and immune mechanisms improves outcomes. Development will remain constrained by more complex trial design and safety monitoring.
07Early-stage patient selection remains restrictive
High confidenceLeqembi is indicated for patients with mild cognitive impairment or mild dementia stages of Alzheimer’s disease, requires confirmation of amyloid pathology and requires a recent baseline MRI followed by additional MRIs during treatment.[20]
Forecast 2027: In 2027, biologic demand should remain concentrated in early Alzheimer’s disease and in patients able to complete biomarker confirmation and MRI monitoring. Broader use in moderate disease is unlikely without new efficacy and safety evidence.
08MRI and biomarker infrastructure expands
High confidenceLeqembi labeling requires amyloid confirmation, a baseline brain MRI and follow-up MRIs after 1, 2, 3 and 6 months of treatment. The 2026 pipeline review found that 27% of trials used a biomarker as a primary outcome measure, alone or alongside a clinical measure.[20][1]
Forecast 2027: In 2027, demand should rise for amyloid and tau testing, MRI capacity and biomarker-qualified trial sites. Blood-based biomarkers may increasingly support screening and monitoring, but MRI will remain important for antibody safety management.
09Home administration improves convenience
High confidenceOn July 13, 2026, the FDA approved the first at-home starting-dose regimen for an Alzheimer’s treatment, allowing eligible patients or caregivers to initiate subcutaneous Leqembi administration at home rather than beginning exclusively with an infusion-center dose.[6]
Forecast 2027: In 2027, home initiation and subcutaneous maintenance should become an important competitive differentiator for anti-amyloid biologics. Adoption will depend on caregiver training, patient selection, payer policies and the ability to manage adverse events outside infusion centers.
10Administration shifts toward subcutaneous dosing
High confidenceThe 2026 Leqembi label provides both intravenous and subcutaneous starting options and allows a weekly subcutaneous maintenance dose after 18 months, alongside intravenous maintenance dosing every four weeks.[20]
Forecast 2027: By 2027, subcutaneous delivery should gain share among patients who value convenience and among providers seeking to reduce infusion-center burden. Intravenous dosing will remain important where clinical supervision and established administration infrastructure are preferred.
04 Statistics
Technology
The pipeline contains 54 biological disease-targeted therapies across 192 Alzheimer’s trials on January 1, 2026, with Phase 3 at 11 among 21.
R&D, patents and design rights in the alzheimers biologics industry
- 54 biological disease-targeted therapies were in 192 Alzheimer’s disease clinical trials globally on January 1, 2026, classified using the Common Alzheimer’s Disease Research Ontology; this is the closest available category-level proxy for Alzheimer’s biologics.[1]
- 22 biological disease-targeted therapies were in Phase 2 Alzheimer’s disease trials globally on January 1, 2025, among 60 Phase 2 disease-targeted therapies.[1]
- 11 biological disease-targeted therapies were in Phase 3 Alzheimer’s disease trials globally on January 1, 2026, among 21 Phase 3 disease-targeted therapies.[1]
- 42 biological disease-targeted therapies were in 182 Alzheimer’s disease clinical trials globally on January 1, 2025, representing 41% of all disease-targeted therapies in the pipeline.[1]
05 Statistics
Market Intelligence
Market context spans USD 4.05 billion in 2022 and USD 6.94 billion in 2025, while a 2030 projection reaches USD 9.51 billion with a 6.6% CAGR.
Market size, volume and shipments in the alzheimers biologics industry
- USD 4.05 billion was the estimated 2022 global Alzheimer’s therapeutics market size; the broader category includes biologics alongside small-molecule and symptomatic treatments, measured as revenue.[2]
- USD 6.94 billion was the estimated 2025 global Alzheimer’s disease treatment market size; the category includes immunoglobulins and monoclonal antibodies as well as non-biologic treatments, measured as revenue.[3]
Forecast growth and shipments in the alzheimers biologics industry
- USD 9.51 billion is the projected 2030 global Alzheimer’s disease treatment market size, implying a 6.6% CAGR during 2025–2030; the category includes monoclonal antibodies and other treatments.[3]
- A 19.99% CAGR is forecast for the global Alzheimer’s therapeutics market from 2023 through 2030; the market definition includes biologics within the broader therapeutics category.[2]
- A 6.6% CAGR is forecast for the global Alzheimer’s disease treatment market from 2025 through 2030, driven partly by monoclonal-antibody adoption; the category is broader than biologics alone.[3]
- USD 15.19 billion is the projected 2030 global Alzheimer’s therapeutics market size, with a 19.99% CAGR from 2023 to 2030; the category includes biologics and non-biologic Alzheimer’s treatments.[2]
Company counts and size structure in the alzheimers biologics industry
- 42 biological therapies represented 41% of the 102 disease-targeting therapies in the 2025 Alzheimer’s drug-development pipeline, which contained 138 drugs across 182 trials.[1]
- 23 biologic disease-targeting therapies were among 84 drugs in Phase 2 Alzheimer’s trials on January 1, 2026, representing 38% of Phase 2 disease-targeting therapies.[1]
- 24 biologic disease-targeting therapies were among 45 drugs in Phase 1 Alzheimer’s trials on January 1, 2026, representing 62% of Phase 1 disease-targeting therapies.[1]
Key questions about the alzheimers biologics industry
How big is the Alzheimer’s therapeutics market used for biologics context in 2022 and 2025?
What growth rates are forecast for Alzheimer’s treatment markets through 2030?
Which companies lead the alzheimers biologics industry?
How is the Alzheimer’s biologics pipeline trending beyond anti-amyloid in 2026?
Where does clinical development volume sit geographically in the 2026 Phase 3 pipeline?
What constraints and selection requirements shape patient access for approved biologics?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Samuel Norberg. (2026, November 19). Alzheimers Biologics Industry Statistics. Gitnux. https://gitnux.org/alzheimers-biologics-industry-statistics
Samuel Norberg. "Alzheimers Biologics Industry Statistics." Gitnux, 19 Nov 2026, https://gitnux.org/alzheimers-biologics-industry-statistics.
Samuel Norberg. 2026. "Alzheimers Biologics Industry Statistics." Gitnux. https://gitnux.org/alzheimers-biologics-industry-statistics.
Sources & references
20 sources cited across this report
alz-journals.onlinelibrary.wiley.com
grandviewresearch.com
thebusinessresearchcompany.com
sec.gov
- leqembi.com
fda.gov
statnews.com
dailymed.nlm.nih.gov
cms.gov
kisunla.lilly.com
eisai.com
roche.com
- acimmune.com
investors.biogen.com
- ir.prothena.com
investors.denalitherapeutics.com
- alzinova.com
- ir.acimmune.com
- vaxxinity.com
accessdata.fda.gov